Kamapharm

Kamapharm is a biotechnology company focused on the development of novel therapeutic agents for cardiovascular and renal diseases. The company specializes in the design and optimization of small molecule and peptide-based drugs targeting the renin-angiotensin system. Their research primarily centers on modulating angiotensin receptors to treat conditions such as hypertension and diabetic nephropathy. Kamapharm aims to bridge the gap between early-stage academic discovery and clinical development through strategic partnerships and internal R&D. The company is currently in the pre-clinical stage with several lead candidates undergoing optimization.